A clinical-stage drug development company focused on overcoming cancer drug resistance
onward-therapeutics.comLinkedInTaipei, TaiwanBiotechFounded 2019
19 sources · checked 3 times, last 16h ago
FinSMEs and BeBeez display November 18, but the company's release gives a November 17 dateline; the company release controls.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $28M $118M to date NT$900 million (approximately US$28 million) | 2026-11-17 | not stated | 15 outlets. #68 in Trending |
19 sources · checked 3 times, last 16h ago [ VERIFIED ] read against 4 of 19 sources FinSMEs and BeBeez display November 18, but the company's release gives a November 17 dateline; the company release controls. | ||||
Onward Therapeutics is a clinical-stage oncology company that identifies promising technologies and advances cancer medicines for people with hard-to-treat or drug-resistant cancers.
Checked against 10 sources yesterday
Also named as backers in company research: BroadVision Group, France 2030 plan "Biotherapies and bioproduction of innovative therapies"